Recall: Atovaquone
Apr. 2023Pharmacy Updates
Camber Pharmaceuticals Inc. is recalling Atovaquone Oral Suspension, USP 750 mg/5 mL, lot #E220182 with an expiration date of 12/2023, due to possible bacterial contamination in the product. This drug is used for the prevention and treatment of a lung infection called Pneumocystis jiroveci pneumonia (PCP) in adults and children 13 years old and older who cannot tolerate other medicines, such as trimethoprim-sulfamethoxazole. Read the full text of the Atovaquone recall.
Recent Announcements
Voluntary nationwide recall: Famotidine (Fresenius – November)
Fresenius Kabi USA, LLC is recalling three lots (6133156, 6133194, and 6133388) of Famotidine Injection, USP, 20 mg per 2 mL. Famotidine is used to treat excessive secretion of stomach acid or stomach ulcers.Nov. 2025Pharmacy Updates
Medicaid provider update: High-cost Medicaid drug billing
Billing requirements for Medicaid-covered drugsNov. 2025Important Notices
Training Webinar: Conversio Health COPD Management Program
Please join us for a live training webinar for primary care providers and pulmonologists by UPMC Health Plan that will provide an overview of a comprehensive COPD management program from Conversio Health.Nov. 2025Education/Webinars